Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.825 USD | -5.93% | +10.37% | -39.87% |
Apr. 11 | Ocuphire Pharma Enrolls 1st Patient in Phase 3 Trial of Visual Acuity Treatment | MT |
Apr. 11 | Ocuphire Pharma, Inc. Announces Global License Agreement with Viatris Inc | CI |
Financials (USD)
Sales 2024 * | 28.05M | Sales 2025 * | 72.09M | Capitalization | 49.68M |
---|---|---|---|---|---|
Net income 2024 * | -1M | Net income 2025 * | 39M | EV / Sales 2024 * | 1.77 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.69 x |
P/E ratio 2024 * |
291
x | P/E ratio 2025 * |
1.09
x | Employees | 14 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.49% |
Latest transcript on Ocuphire Pharma, Inc.
1 day | -5.41% | ||
1 week | +12.80% | ||
Current month | +16.72% | ||
1 month | +1.09% | ||
3 months | -26.59% | ||
6 months | -39.14% | ||
Current year | -38.54% |
Managers | Title | Age | Since |
---|---|---|---|
George Magrath
CEO | Chief Executive Officer | 40 | Oct. 31 |
Nirav Jhaveri
DFI | Director of Finance/CFO | 46 | Feb. 13 |
Barbara Withers
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Rodgers
BRD | Director/Board Member | 57 | 20-10-31 |
James Manuso
BRD | Director/Board Member | 75 | 18-12-31 |
Susan Benton
BRD | Director/Board Member | 59 | 20-10-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-08 | 1.825 | -5.93% | 163 140 |
24-05-07 | 1.94 | -3.48% | 186,679 |
24-05-06 | 2.01 | +1.01% | 228,426 |
24-05-03 | 1.99 | +7.57% | 350,777 |
24-05-02 | 1.85 | +12.80% | 663,166 |
Delayed Quote Nasdaq, May 08, 2024 at 03:22 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-38.54% | 49.68M | |
+33.16% | 700B | |
-4.94% | 358B | |
+18.96% | 330B | |
+3.40% | 287B | |
+15.70% | 236B | |
+6.68% | 202B | |
-9.08% | 197B | |
+6.13% | 161B | |
-1.82% | 157B |
- Stock Market
- Equities
- OCUP Stock